A Roadmap for Potential Improvement of Newborn Screening for Inherited Metabolic Diseases Following Recent Developments and Successful Applications of Bivariate Normal Limits for Pre-Symptomatic Detection of MPS I, Pompe Disease, and Krabbe Disease

Authors

Kabir Jalal, University at Buffalo
Randy L Carter, University at Buffalo
Amy Barczykowski, University at Buffalo
Shunji Tomatsu, Thomas Jefferson UniversityFollow
Thomas J Langan, University at Buffalo

Document Type

Article

Publication Date

11-15-2022

Comments

This article is the author’s final published version in International Journal of Neonatal Screening, Volume 8, Issue 4, November 2022, Article number 61.

The published version is available at https://doi.org/10.3390/ijns8040061. Copyright © Jalal et al.

Abstract

The mucopolysaccharidoses (MPS), Pompe Disease (PD), and Krabbe disease (KD) are inherited conditions known as lysosomal storage disorders (LSDs) The resulting enzyme deficiencies give rise to progressive symptoms. The United States Department of Health and Human Services' Recommended Uniform Screening Panel (RUSP) suggests LSDs for inclusion in state universal newborn screening (NBS) programs and has identified screening deficiencies in MPS I, KD, and PD NBS programs. MPS I NBS programs utilize newborn dried blood spots and assay alpha L-iduronidase (IDUA) enzyme to screen for potential cases. Glycosaminoglycans (GAGs) offer potential as a confirmatory test. KD NBS programs utilize galactocerebrosidase (GaLC) as an initial test, with psychosine (PSY) activity increasingly used as a confirmatory test for predicting onset of Krabbe disease, though with an excessive false positive rate. PD is marked by a deficiency in acid α-glucosidase (GAA), causing increased glycogen, creatine (CRE), and other biomarkers. Bivariate normal limit (BVNL) methods have been applied to GaLC and PSY activity to produce a NBS tool for KD, and more recently, to IDUA and GAG activity to develop a NBS tool for MPS I. A BVNL tool based on GAA and CRE is in development for infantile PD diagnosis. Early infantile KD, MPS I, and PD cases were pre-symptomatically identified by BVNL-based NBS tools. This article reviews these developments, discusses how they address screening deficiencies identified by the RUSP and may improve NBS more generally.

Recommended Citation

Jalal, Kabir; Carter, Randy L; Barczykowski, Amy; Tomatsu, Shunji; and Langan, Thomas J, "A Roadmap for Potential Improvement of Newborn Screening for Inherited Metabolic Diseases Following Recent Developments and Successful Applications of Bivariate Normal Limits for Pre-Symptomatic Detection of MPS I, Pompe Disease, and Krabbe Disease" (2022). Department of Pediatrics Faculty Papers. Paper 128.
https://jdc.jefferson.edu/pedsfp/128

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 License.

PubMed ID

36412587

Language

English